Active Comparator: Phase 3 – Standard of Care
Investigator’s choice of standard of care between everolimus, sunitinib, octreotide, or lanreotide.
Drug: Everolimus 10 mg
Everolimus 10 mg daily by mouth
Drug: Sunitinib 37.5 MG
Sunitinib 37.5 mg daily by mouth
Drug: Octreotide LAR 60 MG Injection
High-dose octreotide LAR 60 mg Q4W by i.m. injection
Drug: Lanreotide 120Mg Sa Susp Inj Syringe
High dose frequency lanreotide 120 mg Q2W by deep s.c. injection
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
